Imatinib Recruiting Phase 3 Trials for Chronic Myeloid Leukemia (CML) Treatment

RecruitingTreatment3 IdentifierTitleDrugs
NCT02326311Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
NCT02174445An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years